Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma
- PMID: 17720243
- DOI: 10.1016/j.leukres.2007.07.012
Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma
Abstract
Anaplastic large cell lymphoma (ALCL) comprises a group of non-Hodgkin lymphomas characterized by the expression of the CD30/Ki-1 antigen. A subset of ALCL is characterized by chromosomal translocations involving the anaplastic lymphoma kinase (ALK) gene on chromosome 2. While the most common translocation is the t(2;5)(p23;q35) involving the nucleophosmin (NPM) gene on chromosome 5, up to 12 other translocations partners of the ALK gene have been identified. One of these is the t(1;2)(q25;p23) which results in the formation of the chimeric protein TPM3-ALK. While several of the signaling pathways induced by NPM-ALK have been elucidated, those involved in ALCLs harboring TPM3-ALK are largely unknown. In order to investigate the expression profiles of ALCLs carrying the NPM-ALK and TPM3-ALK fusions, we carried out cDNA microarray analysis of two ALCL tissue samples, one expressing the NPM-ALK fusion protein and the other the TPM3-ALK fusion protein. RNA was extracted from snap-frozen tissues, labeled with fluorescent dyes and analyzed using cDNAs microarray containing approximately 9,200 genes and expressed sequence tags (ESTs). Quantitative fluorescence RT-PCR was performed to validate the cDNA microarray data on nine selected gene targets. Our results show a significant overlap of genes deregulated in the NPM-ALK and TPM-ALK positive lymphomas. These deregulated genes are involved in diverse cellular functions, such as cell cycle regulation, apoptosis, proliferation, and adhesion. Interestingly, a subset of the genes was distinct in their expression pattern in the two types of lymphomas. More importantly, many genes that were not previously associated with ALK positive lymphomas were identified. Our results demonstrate the overlapping and unique transcriptional patterns associated with the NPM-ALK and TPM3-ALK fusions in ALCL.
Similar articles
-
Mapping of genomic t(2;5)(p23;q35) break points in patients with anaplastic large cell lymphoma by sequencing long-range PCR products.Hematopathol Mol Hematol. 1998;11(3-4):173-83. Hematopathol Mol Hematol. 1998. PMID: 9844824
-
Identification of anaplastic lymphoma kinase variant translocations using 5'RACE.Methods Mol Med. 2005;115:295-314. doi: 10.1385/1-59259-936-2:295. Methods Mol Med. 2005. PMID: 15998975
-
A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation.Blood. 1999 May 1;93(9):3088-95. Blood. 1999. PMID: 10216106
-
The NPM/ALK gene fusion in the pathogenesis of anaplastic large cell lymphoma.Cancer Surv. 1997;30:59-75. Cancer Surv. 1997. PMID: 9547986 Review.
-
Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.Leukemia. 2000 Sep;14(9):1533-59. doi: 10.1038/sj.leu.2401878. Leukemia. 2000. PMID: 10994999 Review.
Cited by
-
Anaplastic large cell lymphoma: changes in the World Health Organization classification and perspectives for targeted therapy.Haematologica. 2009 Jul;94(7):897-900. doi: 10.3324/haematol.2009.008250. Haematologica. 2009. PMID: 19570751 Free PMC article.
-
Strategy for Pediatric Patients with Relapsed or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: A Review.Cancers (Basel). 2023 Dec 7;15(24):5733. doi: 10.3390/cancers15245733. Cancers (Basel). 2023. PMID: 38136278 Free PMC article. Review.
-
NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases.J Signal Transduct. 2012;2012:123253. doi: 10.1155/2012/123253. Epub 2012 Jul 18. J Signal Transduct. 2012. PMID: 22852078 Free PMC article.
-
Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.Expert Rev Anticancer Ther. 2009 Mar;9(3):331-56. doi: 10.1586/14737140.9.3.331. Expert Rev Anticancer Ther. 2009. PMID: 19275511 Free PMC article. Review.
-
A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment.Oncotarget. 2017 Dec 9;8(69):113895-113909. doi: 10.18632/oncotarget.23040. eCollection 2017 Dec 26. Oncotarget. 2017. PMID: 29371955 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous